MIND4-17
SIGMA/SML2021 - ≥98% (HPLC)
Synonym: 5-
CAS Number: 345989-24-4
Empirical Formula (Hill Notation): C20H15N5O3S
Molecular Weight: 405.43
MDL Number: MFCD01899657
Linear Formula: C20H15N5O3S
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to brown |
| form | powder |
| InChI | 1S/C20H15N5O3S/c26-25(27) |
| InChI key | OZUBDKIROJPQGE-UHFFFAOYSA |
| SMILES string | O=[N+]([O-])C(C=C1)=CN=C1 |
| solubility | DMSO: 2 mg/mL, clear (warmed) |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | KEAP1 covalent modifier with therapeutic potential for Huntington′s disease by promoting NRF2 activation. |
| Biochem/physiol Actions: | MIND4-17 is a potent NRF2 (nuclear factor erythroid 2-related factor 2) activator that covalently modifies a critical stress-sensor cysteine (C151) in the BTB domain of the E3 ligase substrate adaptor protein Kelch-like ECH-associated protein 1 (KEAP1), the primary negative regulator of NRF2. MIND4-17 induces NRF2 activation responses in neuronal and non-neuronal cultures (effective conc. 0.1-10 μM) of human, mouse, and rat origins. In addition, MIND4-17 effectively reduces endotoxin-induced IL-6 release from WT as well as YAC128 HD mutant mice-derived primary microglia and astrocytes, however, NRF2 induction by MIND4-17 is shown to be compromised in human Huntington′s diseased (HD) relative to non-disesed neural stem cells due to suppressive influence of the expanded CAG repeat mutation on pathway activation. |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |